F-box and leucine rich repeat protein 7Genealiases: FBL6 · FBL7
Q-omics provides the consensus-scored FBXL7 profile across patient tissues and cancer cell-line models. FBXL7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FBXL7 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, FBXL7 RNA expression shows 19,002 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where FBXL7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL7 survival associations across molecular data types. FBXL7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL7 RNA expression–survival associations across cancer types. High FBXL7 expression shows unfavorable associations in UVM, ACC, BLCA and LGG, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FBXL7 RNA expression.
This table summarizes FBXL7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FBXL7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL7 shows lower tumor expression in COAD, BLCA, KICH and LUAD and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher FBXL7 RNA expression in tumor versus normal tissue (log2 FC = +0.995, t-test p < 0.001).
This table shows molecular features associated with FBXL7 in patient tissues and cancer cell lines. In patient samples, FBXL7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
